Osimertinib in central nervous system progressive EGFR-mutant lung cancer: do we need to detect T790M?
- PMID: 32890631
- DOI: 10.1016/j.annonc.2020.08.2234
Osimertinib in central nervous system progressive EGFR-mutant lung cancer: do we need to detect T790M?
Conflict of interest statement
Disclosure SP served as consultant at UPPthera; M-JA received honorarium from AstraZeneca, BMS, MSD, ONO, and Roche; and served as consultant or advisor at AstraZeneca, BMS, Takeda, MDS, Novartis, Roche, and Alpha pharmaceutical.
Comment on
-
Osimertinib in CNS-progressive EGFR-mutant lung cancer: do we need to detect T790M?Ann Oncol. 2020 Nov;31(11):1581-1582. doi: 10.1016/j.annonc.2020.07.021. Epub 2020 Aug 13. Ann Oncol. 2020. PMID: 32798688 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
